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Abstract: Hypoxia is a common feature of neurodegenerative diseases, including Alzheimer’s disease
that may be responsible for disease pathogenesis and progression. Therefore, the hypoxia-inducible
factor (HIF)1 system, responsible for hypoxic adaptation, is a potential therapeutic target to combat
these diseases by activators of cytoprotective protein induction. We have selected a candidate molecule
from our cytoprotective hydroxyquinoline library and developed a novel enantioselective synthesis
for the production of its enantiomers. The use of quinidine or quinine as a catalyst enabled the
preparation of enantiomer-pure products. We have utilized in vitro assays to evaluate cytoprotective
activity, a fluorescence-activated cell sorting (FACS) based assay measuring mitochondrial membrane
potential changes, and gene and protein expression analysis. Our data showed that the enantiomers of
Q134 showed potent and similar activity in all tested assays. We have concluded that the enantiomers
exert their cytoprotective activity via the HIF1 system through HIF1A protein stabilization.
Keywords: 8-hydroxyquinoline; Alzheimer’s disease; Betti reaction; enantioselective synthesis;
cytoprotection; neurodegeneration; mitochondrial membrane potential; HIF1A
1. Introduction
Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease of the brain
which leads to loss of memory and cognitive functions. The pathological hallmarks of the disease are
amyloid beta deposition, neurofibrillary tangles, neuroinflammation, and neuronal loss in the patient’s
brain [1]. Two forms of AD are defined generally: a familial early-onset form linked to gene mutations
in amyloid β precursor protein and presenilin and a sporadic late-onset form. More evidence suggests
that environmental risk factors play an important role in the onset and development of sporadic AD
which constitute the majority of AD cases [2,3].
Hypoxia is a common etiology in neurodegenerative diseases, including AD [4]. Occurrence and
susceptibility to AD is higher in individuals suffering from cerebral ischemia and stroke in which
hypoxic conditions occur. Hypoxia may be responsible for promoting the pathogenesis and progression
of AD through several factors: increasing the processing and inhibiting the clearance of amyloid beta,
promoting tau hyperphosphorylation and facilitation of neuronal death [5,6].
Molecules 2019, 24, 4269; doi:10.3390/molecules24234269 www.mdpi.com/journal/molecules
Molecules 2019, 24, 4269 2 of 13
Reduction of blood supply leading to hypoxic condition is known to activate cellular responses
mainly controlled by hypoxia-inducible factors (HIFs). Hypoxia-inducible factors are heterodimeric
transcription factors consisting of an α- and a β-subunit belonging to the basic helix-loop-helix
Per-Arnt-Sim (bHLH)-PAS protein superfamily. Hypoxia-inducible factor 1 alpha (HIF1A) protein
level is regulated by protein degradation and stabilization under normoxic or hypoxic conditions.
HIF1A is stabilized under low O2 levels through the inhibition of a ubiquitination pathway regulated
by prolyl hydroxylase enzymes (PHDs). Translocation to the nucleus facilitates its binding to the
hypoxia response element (HRE) and induces the expression of hypoxia related genes that encode e.g.,
vascular endothelial growth factor (VEGF) glucose transporters and glycolytic enzymes [7].
These HIF1 regulated genes trigger an endogenous neuroprotective response that has a role in
neuronal survival [8]. It has been shown that stabilization of HIF1A through proteasome inhibition [9]
or the use of heavy metals (cobalt or nickel) or metal chelation [8] attenuated hypoxia related
damage. Furthermore, several studies concluded that oxyquinoline analogs are potent inhibitors of
prolyl-4-hydroxylases and stabilize HIF1A [10–12].
Following the development of high-throughput phenotypic assays and subsequent gene expression
analysis, the integration of cell-based assays with activity-based approaches allow us to identify small
molecules interrogating cellular phenotypic alterations, changes in transcript signature or protein
expression levels [13].
Previously, we developed a novel cell-microelectronic sensing technique (RT-CES)-based
cytoprotective screening assay, and revealed Betti-bases as being a new subclass of potent cytoprotective
agents; where 8-hydroxyquinoline (8HQ), benzocain, and benzaldehyde motifs emerged as suitable
candidates for a hit-to-lead optimization [14]. Systematic preparative efforts led to the analogue Q50,
which was proven to be highly potent in improving cardiac functional recovery of ischemic/reperfused
myocardium in rats [15]. Recently, a 48-membered Betti library was synthesized to screen for
neuroprotective compounds by the utilization of formic acid mediated industrial-compatible coupling
with sets of aromatic primary amines such as anilines, oxazoles, pyridines, and pyrimidines, with
(hetero)aromatic aldehydes and 8-hydroxiquinoline derivatives [16]. To the best of our knowledge, the
asymmetric Betti reaction incorporating 8-hydroxyquinoline has not been studied so far.
Here, we describe the enantioselective synthesis of a potent 8-hydroxyquinoline-based Betti
derivative, the cytoprotective effects of the enantiomers on neuronal cells as well as their effects on
transcription and protein expression.
2. Results
2.1. Enantioselective Synthesis of Q134R and Q134S
As previously reported, a formic acid-mediated three-component assembly of 8HQ (1),
4-(trifluoromethyl)benzaldehyde (2), and 4-methylpyrimidin-2-amine (3) gave access to racemic
Q134 [16]. In order to prepare pure enantiomers, cinchona alkaloids were firstly tested in the Betti-3CR,
giving no conversion. However, excellent enantiomer ratios were obtained when quinidine or quinine
were employed in the presence of formic acid (Scheme 1). It should be noted, that nearly a stoichiometric
amount of catalyst and acid was applied, however, these reaction conditions were determined to
be optimal for industrial synthesis, therefore further optimization was not performed. The chirality
transfer might be explained via the formation of an ion pair between the catalyst and 1, generating a
chiral transition complex, which can react with the imine formed in situ. The absolute configuration
of each enantiomer was supported by vibrational circular dichroism (VCD) and IR measurements.
Moreover, the well-established protocol allowed the synthesis of Q134R and Q134S in an asymmetric
fashion on a multigram scale [17].
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Figure 1. Cytoprotective activity of Q134 and its two enantiomers. (A) Cytoprotective activity 24 h
after treatment. (B) Calculated IC50 values of the racemic mixture and the two enantiomers.
2.3. Mitochondrial Membrane Depolarization Following Oxidative Stress Is Reversed by Treatment with Q134R
and Q134S
Mitochondrial dysfunction is a prominent feature in neurodegenerative diseases, resulting in
reactive oxygen specie generation. Mit chondrial membra e potential (MMP) is affected by oxidative
stress and may serve a a trigger for programmed cell death. Previously, we have shown that 8HQ
analogs were able to normalize the mitochondrial membrane pot ntial of U251 MG cells followi g
oxidative stress in a dose depe dent manner [16]. Here, we investig t d whether Q134R and Q134S
sh w any difference in their ctivity. U251 MG cells were treat d with H2O2 and with an increasing
dose of Q134R and Q134S and JC-1 staining was determined with flow cytometry after 2 h of incubation
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(Figure 2). Both compounds showed potent activity, but no difference was detected between Q134R
and Q134S.
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Figure . Mitochondrial membrane depolarization assay. Treatment with th synthesized nantiom rs
reversed the mitochondrial membrane potential changes caused by oxidative stress. Y axis represents
the percentage of cells with depolarized mitochondria. ** p < 0.01; *** p < 0.001 (pairwise comparison
of Q134R or Q134S treatment to only H2O2 treated cells; Student’s t-test).
2.4. Q134R and Q134S Stabilize HIF1A Protein In Vitro
Our compounds showed potent activity in cytoprotection assays and previously we have shown
that members of our original 8HQ library induced hypoxia related genes under HIF1A regulation.
Previous studies showed that 8HQ analogs inhibit prolyl hydroxylases and as a result stabilize HIF1A
protein. Therefore, we hypothesized that their activity was related to HF1 activity. U251 MG cells were
treated with increasing doses of Q134R or Q134S, and with CoCl2 a compound known to stabilize
HIF1A protein. After 3 h, cells wer collected and HIF1A expression was determined by Wester blot
na ysis. Robust bands wer detected in case of both nantiomers, proving that Q134R and Q134S
stabilized HIF1A in a d se depe ent manner. As expect d rom the cy oprotection study, HIF1A
protein stabilization showed o significant enantiomer s lectivity (Figure 3).
2.5. Gene Expression Analysis. Q134R and Q134S Induce Hypoxia Related Genes and Glucose
Transporter Expression
We carried out a quantitative real-time PCR (QRT-PCR) study to determine any differences in
modulation of gene expression levels of HIF1 regulated genes by the enantiomers of Q134. U251
MG cells were treated with an increasing dose of both Q134R or Q134S. After 6 h of incubation
expression, levels of heme oxygenase 1 (HMOX1), vascular endothelial growth factor (VEGF), and
glucose transporter 1 (GLUT1) were determined. Treatments with both enantiomers resulted in
significant gene activation at concentrations, where cytoprotective activity was detected (see Figure 1).
Again, no significant differences were detected in the activity of the two enantiomers (Figure 4).
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2.6. Inhibition of HIF1A Translation Abolished Cytoprotective Activity
To validate HIF1A as a target of Q134 we designed an experiment where HIF1A translation was
blocked and the cytoprotection activity of Q134R enantiomer was tested with no HIF1A present. We
used KC7F2, a HIF1A translation inhibitor to deplete the cells from the HIF1A protein [18]. Western blot
analysis showed that treatment with 30 µM of KC7F2 blocked HIF1A translation after 24 h (Figure 5,
lane 4).
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depleted the treated cells from HIF1A. Q134R treatment only partially restored HIF1A expression.
(A) Western blot analysis of treated U251 MG cells, (B) Quantification of HIF1A protein expression in
treated U251 MG cells.
Consequently, we tested whether Q134R was able to restore HIF1A expression in cells depleted of
HIF1A with KC7F2 (30 µM, 24 h). Western blot analysis showed (Figure 5) that Q134R was partially
able to restore HIF1A, but only at the higher 330 nM concentration. The HIF1A level in cells treated
with 110 nM Q134R was below control.
Finally, we tested how cytoprotection of Q134R was affected in cells depleted of HIF1A. Therefore,
U251 MG cells were pretreated with KC7F2 for 24 h followed by treatment with Q134R and H2O2. An
additional 24 h later cell viability was measured with the resazurin reagent. Similarly to the protein
expression study (Figure 5), two concentrations were tested: 110 and 330 nM. Inhibitor treatment
decreased Q134R activity at both tested concentrations. At 330 nM Q134R concentration, a 50% decrease
of cytoprotective activity was detected while at 110 nM cytoprotection was abolished completely
(Figure 6). For cytoprotection inhibition, similar results were recorded for Q134S (data not shown).
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Figure 6. Inhibition of HIF1A translation abolished the cytoprotective activity of Q134R. U251 MG
cells were pretreated with KC7F2 (30 µM, 24 h) to block HIF1A translation. Then, cells were treated
with Q134R (Q 110 or 330 nM) and H2O2 (500 µM). ** p < 0.01 (St ent’s t-test).
3. Discussion
Much importance in hypoxic signaling has been attributed to hypoxia-inducible factors, capable of
activating a battery of genes including genes involved in glucose uptake and metabolism, extracellular
pH control, angiogenesis, erythropoiesis, mitogenesis, and apoptosis [19]. Hypoxia-inducible factor-1
is a phosphorylation-dependent and redox-sensitive transcription factor that regulates neuroprotection
during hypoxic conditions, and upregulation of HIF levels has been shown to be beneficial for ischemic
diseases, stem cell proliferation [20], and transplantation [21]. As hypoxia is a prominent feature of
neurodegenerative diseases such as AD, compounds that are able to modulate HIF-regulated targets
may provide an avenue for the rescue of cells affected through their cytoprotective activity. Several
research groups and drug discovery companies suggest that the HIF1 system is a potential therapeutic
target to combat neurodegenerative diseases by designing and developing activators for cytoprotective
protein induction.
We have selected Q134 as our candidate molecule from a previous study that included the
development and investigation of a library of cytoprotective 8-hydroxyquinoline analogs. Here, we
describe, for the first time, an asymmetric synthesis yielding enantiomer pure 8HQ products. The
two synthesized enantiomers of Q134 were investigated for their cytoprotective activity and for their
mechanism of action. It was apparent that both compounds acted identically as evidenced by their
modulation of mitochondrial membrane potential, HIF1A protein and HIF1 regulated gene expression.
Both Q134R and Q134S stabilized HIF1A at doses that were similar to their IC50 values in cytoprotection
assays. This result corresponds well with previous findings that 8HQ analogs were inhibitors of PHDs
that regulate HIF1A degradation [10,22]. As HIF1A stabilization was sufficient for cytoprotection
in our assays (CoCl2 was cytoprotective, data not shown), we hypothesized that the HIF1 system
was the main target that facilitated our compound’s cytoprotective activity. Depletion of cells from
HIF1A using KC7F2, a HIF1A translation inhibitor resulted in complete loss of cytoprotective activity
of Q134R. Further investigation of the direct target of Q134R may follow since our HIF1A protein
expression experiments showed that KC7F2 completely blocked HIF1A production but subsequent
Q134R treatment restored its presence partially. If Q134R only stabilized HIF1A, then no HIF1A should
reappear after Q134R treatment in depleted cells. Either, KC7F2 is a partial inhibitor of translation
and Q134R stabilizes the remaining HIF1A protein or Q134R interferes with the regulation of HIF1A
translational inhibition of KC7F2.
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Although we were not able to show significant differences in activity of the synthesized enantiomers,
we selected Q134R as the clinical candidate, as it showed slightly better activity in cellular assays and
in Western blot experiments.
It is crucial to obtain enantiomer pure versions of chiral molecules in drug development for their
exact characterization in biological systems to identify target specific mechanism of action as well as
to reveal their possible off-target effects. Therefore, development of an enantioselective synthesis is
preferential against separation purification approaches. Moreover, this process provides an invaluable
tool to produce these enantiomers in industrial scale.
Q134 is a central member of our central nervous system (CNS) drug development program that
focuses on a multi-target approach to combat a complex disease such as AD. Therefore, to achieve an
optimal co-modulation of several targets and to determine toxicity profiles it is important to evaluate
the activity of each enantiomer independently. Detailed target identification and validation of the
clinical candidate is in progress.
4. Materials and Methods
4.1. Enantioselective Synthesis of Q134R and Q134S
4.1.1. General Information
NMR analysis and chromatography were performed as previously described [23]. Briefly, NMR
spectra were recorded at 298 K on a Bruker Ascend 500 (Bruker, Billerica, MA, USA) with 5 mm BBO
Prodigy Probe in CDCl3-d1 or DMSO-d6. The chemical shifts are reported in δ (ppm) relative to the
internal standard tetramethylsilane (TMS) or the residual solvent signal. Data are reported as follows:
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet
of doublet, dt = doublet of triplet, etc.) and integration. Chromatographic purification of the products
was performed on Merck silica gel 60, particle size 0.063–0.200 mm. thin layer chromatography (TLC)
was performed on fluorescent-indicating plates (aluminum sheets precoated with silica gel 60F254,
1.05554, Merck, (Kenilworth, NJ, USA), and visualization was achieved by UV light (254 nm) or by
staining with basic potassium permanganate solution. Chiral HPLC measurements were performed
by Shimadzu LC10 series (Shimadzu, Kyoto, Japan) using Phenomenex Lux 5u Cellulose-4 column
(Phenomenex, Torrance, CA, USA). All reagents and solvents were commercially available and used
without further purification.
4.1.2. Synthesis of (R)-7-((4-methylpyrimidin-2-ylamino)(4-trifluoromethyl)phenyl)methyl)quinolin-
8-ol (Q134R)
Quinidine (16.22 g, 50 mmol, 0.5 equiv.), formic acid (3.87 g, 84 mmol, 0.84 equiv.),
2-amino-4-methylpyrimidine (10.91 g, 100 mmol, 1.0 equiv.), 4-trifluoromethylbenzaldehyde (17.41 g,
100 mmol, 1.0 equiv.), and 8-hydroxyquinoline (17.42 g, 120 mmol, 1.2 equiv.) was added to a stirred
solution of acetonitrile (180 mL) in a 500 mL round bottom flask. The reaction mixture was stirred
at reflux temperature under an inert atmosphere for 16 h. The mixture was concentrated under
reduced pressure to approx. one-third of the reaction mixture volume. The residue was diluted with
dichloromethane (100 mL). The solution was extracted with 1 M NaOH solution (6 × 50 mL). The
organic phase was evaporated. The residue was taken up in toluene (100 mL), and extracted with
3 M HCl solution (2 × 30 mL). Methyl tert-butyl ether (MTBE, 60 mL) was added to the combined
aqueous layers was and the pH of the biphasic system was adjusted to 4 with 40% NaOH solution.
The precipitated quinidine was filtered, and the filtrate layers were separated. The aqueous layer
was washed with MTBE (2 × 20 mL), and the combined organic layers were dried over sodium
sulfate, filtered, and evaporated. The residue was taken up in MeCN (30 mL), and the mixture was
stirred at room temperature for 16 h. The precipitate was collected, yielding 7.61 g (18.5 mmol, HPLC
purity: 95%) of racemic Q134. The filtrate was then evaporated, and the residue was triturated with
isopropanol (40 mL) to give enantiomerically pure Q134R (5.67 g, 13.8 mmol, yield: 14%, HPLC purity:
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98.9%, ee: 99%); 1H-NMR (500 MHz, DMSO-d6) δ 10.1 (1H, s), 8.85, (1H, dd), 8.30 (1H, dd), 8.15 (1H, d),
8.07 (1H, d) 7.75 (1H, d), 7.65 (2H, d), 7.60 (2H, d), 7.53 (1H, dd), 7.41 (1H, d), 7.09 (1H, d), 6.51 (1H, d),
2.25 (3H, s).
4.1.3. Synthesis of (S)-7-((4-methylpyrimidin-2-ylamino)(4-trifluoromethyl)phenyl)methyl)quinolin-
8-ol (Q134S)
Quinine (16.22 g, 50 mmol, 0.5 equiv.), formic acid (3.87 g, 84 mmol, 0.84 equiv.),
2-amino-4-methylpyrimidine (10.91 g, 100 mmol, 1.0 equiv.), 4-trifluoromethylbenzaldehyde (17.41 g,
100 mmol, 1.0 equiv.), and 8-hydroxyquinoline (17.42 g, 120 mmol, 1.2 equiv.) was added to a stirred
solution of acetonitrile (180 mL) in a 500 mL round bottom flask. The reaction mixture was stirred
at reflux temperature under an inert atmosphere for 6 days. The mixture was concentrated under
reduced pressure to approx. one-third of the reaction mixture volume. The residue was diluted with
dichloromethane (100 mL). The solution was extracted with 1 M NaOH solution (6 × 50 mL). The
organic phase was evaporated. The residue was taken up in toluene (100 mL), and extracted with 3 M
HCl solution (2 × 30 mL). MTBE (60 mL) was added to the combined aqueous layers and the pH of the
biphasic system was adjusted to 4 with 40% NaOH solution. The precipitated quinidine was filtered,
and the filtrate layers were separated. The aqueous layer was washed with MTBE (2 × 20 mL), and the
combined organic layers were dried over sodium sulfate, filtered, and evaporated. The residue was
taken up in MeCN (30 mL), and the mixture was stirred at room temperature for 16 h. The precipitate
was collected, yielding 7.61 g (18.5 mmol, HPLC purity: 95%) of racemic Q134. The filtrate was then
evaporated, and the residue was triturated with isopropanol (40 mL) to give Q134R (5.67 g, 13.8 mmol,
yield: 14%, HPLC purity: 98.9%, ee: 99%); 1H-NMR (500 MHz, DMSO-d6) δ 10.1 (1H, s), 8.85, (1H, dd),
8.30 (1H, dd), 8.15 (1H, d), 8.07 (1H, d) 7.75 (1H, d), 7.65 (2H, d), 7.60 (2H, d), 7.53 (1H, dd), 7.41 (1H, d),
7.09 (1H, d), 6.51 (1H, d), 2.25 (3H, s).
4.2. Cell Culture
U251 MG human glioblastoma cell line was a gift from Szabolcs Bellyei, University of Pecs
(originally obtained from American Type Culture Collection, Manassas, VA, USA). Cells were grown at
37 ◦C under 5% of CO2 and 100% humidity in RPMI medium supplemented with 10% fetal calf serum
(FCS) (Sigma-Aldrich, Budapest, Hungary), and penicillin-streptomycin antibiotics (Life Technologies,
Carlsbad, CA, USA) [24].
4.3. Real-Time CellE Sensing (RT-CES) Cytoprotection Assay
RT cytoprotection assay was performed as previously described [14,16,25]. Briefly, RT-CES
96-well E-plate (BioTech Hungary, Budapest, Hungary) was coated with gelatin solution (0.2% in
PBS, phosphate buffer saline) for 20 min at 37 ◦C, then gelatin was washed twice with PBS solution.
Growth media (50 µL) was then gently dispensed into each well of the 96-well E-plate for background
readings by the RT-CES system prior to the addition of 50 µL of the cell suspension containing 104
U251 MG cells. Plates were kept at room temperature in a tissue culture hood for 30 min prior to
insertion into the RT-CES device in the incubator to allow cells to settle. Cell growth was monitored
overnight by measurements of electrical impedance every 15 min. Continuous recording of impedance
in cells was reflected by cell index value. The next day cells were co-treated with 375 µM H2O2 and
test compounds. Treated and control wells were dynamically monitored over 48 h by measurements
of electrical impedance every 5 min. The raw plate reads for each titration point were normalized
relative to the cell index status right before treatment. Each treatment was repeated in 3 wells per
plate during the experiments. Protection values were calculated with relation to normalized cell index
values of non-treated (100%) and hydrogen peroxide treated cells (0%). The presented IC50 values
(half maximal inhibitory concentration) were determined based on dose-response curves plotted in
GraphPad Prism® 5.
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4.4. Detection of Mitochondrial Membrane Potential
Mitochondrial membrane potential was measured as described previously [16,26]. U251 cells
(6 × 104) were plated in 24-well tissue culture plates (Corning Life Sciences, Tewksbury, MA, USA)
in RPMI 10% FCS and were treated in 500 µL media containing 500 µM H2O2 with or without test
compounds. Untreated controls cells were supplemented with 500 µL cell culture media. After
2 h, the supernatants were harvested. Cells were washed with PBS, trypsinized, pooled with the
corresponding supernatant, and centrifuged (2000 rpm, 5 min). Pellet was resuspended and incubated
for 15 min in 5 µg/mL JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolocarbocyanine iodide,
Chemodex) containing media in a final volume of 300 µL at 37 ◦C. Finally, using FL2 (585/42 nm)–FL1
(530/30 nm) channels, the red–green fluorescence intensity of 6 × 103 events was acquired immediately
on FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA) flow cytometer. Data were analyzed
using CellQuest Pro software (version 6.0, Becton Dickinson) gating out debris. Bar graphs show the
percentage of FL1 positive cells.
4.5. Gene Expression Analysis
Gene expression measurements were performed as previously described [16]. Briefly, U251 MG
cells were seeded in 24-well microtiter plates with 105 cells/well density and incubated overnight.
Cells were treated with either vehicle (solvent control; ≤0.01% DMSO) or with Q134 enantiomers:
Q134R and Q134S at 0.1, 0.25, 0.5, and 1 µM concentration. After 6 h of incubation the medium was
removed and cells were rinsed with PBS. Cells were collected for RNA isolation in RA1 Lysis Buffer
(Macherey-Nagel, Düren, Germany) supplemented with 1% beta-mercaptoethanol. Total RNA was
purified with the Direct-zol kit (Zymo Research, Irvine, CA, USA) according to the manufacturer’s
protocol. Total RNA was converted into cDNA using the High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA) in a volume of 10 µL. Then 0.75 µL cDNA template was used (19 ng)
in each PCR reaction. Quantitative real-time PCR was performed on the Light Cycler 96 instrument
(Roche) with gene-specific primers and SybrGreen protocol. NormFinder software [27] was used
to calculate the most suitable housekeeping genes (TUBB and PPIA) for relative expression ratio
calculation. Table 1 lists the used primer sequences.
Table 1. Primer sequences for quantitative real-time (QRT)-PCR analysis.
Gene Name Abbreviation Forward_Sequence Reverse_Sequence
Tubulin beta class I TUBB ataccttgaggcgagcaaaa ctgatcacctcccagaacttg
Peptidylprolyl isomerase A PPIA atgctggacccaacacaaat tctttcactttgccaaacacc
Heme oxygenase 1 HMOX1 ggcagagggtgatagaagagg agctcctgcaactcctcaaa
Vascular endothelial
growth factor VEGF gcagcttgagttaaacgaacg ggttcccgaaaccctgag
Solute carrier family 2
member 1 GLUT1 ccccatcccatggttcatc tgaggtccagttggagaagc
4.6. Western Blot Analysis
Western blot analysis was performed as described previously [28]. Briefly, U251 MG cells
were treated with test compounds or inhibitor (KC7F2, Selleckchem, Houston, TX, USA). Western
blot samples were obtained by scraping 106 cells from 6-well plates in 250 µL of hot 1× Laemmli
buffer. Then 20 µL samples were run on a 4–15% SDS-PAGE and blotted onto Immobilon P PVDF
(polyvinylidene fluoride) membrane (0.45 µm pore size, Millipore, (Budapest, Hungary). After
blocking with 0.5% nonfat dry milk powder in PBS containing 0.1 % Tween 20, membranes were
labeled 1:700 with HF1 alpha antibody (PA1-16601, ThermoFisher, (Waltham, MA, USA). As secondary
antibodies goat anti-rabbit whole IgG antibodies were used (111-035-003, Jackson ImmunoResearch,
(Cambridgeshire, UK)
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Proteins were visualized using the ECL system (Luminata Forte Western HRP substrate, Millipore,
Budapest, Hungary, # WBLUF0100).
Quantification was carried out using ImageJ software by referring the relative density of HF1
alpha bands to the untreated sample relative density. Data are shown as adjusted relative density by
referring the relative intensity of HF1 alpha bands to the corresponding loading control intensities
(Actin: Sigma-Aldrich, A2103 or GAPDH: Invitrogen, PA1-987).
4.7. Resazurin Viability Assay
Endpoint viability assays were performed as described previously [16]. For cytoprotection assays,
104 U251 MG cells were seeded into each well of 96-well cell culture plates (Costar, Corning Inc.,
Tewksbury, MA, USA) in culture medium containing 10% FCS. The following day cells were treated
with test compounds in the presence of 500 µM H2O2 (Sigma-Aldrich). Cell viability was recorded
24 h after treatment. Resazurin reagent (Sigma-Aldrich) was dissolved in phosphate buffered saline
(PBS, pH 7.4) at 0.15 mg/mL concentration, sterile filtered (0.22 µm, Merck Millipore), aliquoted, and
stored at −20 ◦C. Samples were treated with a final concentration of 25 µg/mL resazurin. After 2 h
of incubation at 37 ◦C 5% CO2, fluorescence (530 nm excitation/580 nm emission) was recorded on a
multimode microplate reader (Cytofluor4000, PerSeptive Biosytems, Framingham, MA, USA). Viability
was calculated in relation to untreated control cells and blank wells containing media without cells.
4.8. Statistical Analysis
Statistical analysis was performed using two-tailed, Student’s t-test to evaluate the statistical
significance (set at * p < 0.05, ** p < 0.01, *** p < 0.001) between two given experimental groups.
5. Conclusions
We selected a candidate molecule from our library of cytoprotective 8-hydroxyquinoline analogs.
We developed an asymmetric synthesis methodology to produce enantiomer pure 8HQ products for
the first time. The biological activity of the two synthesized enantiomers of Q134 were investigated
and found to be identical in relation to the HIF1 system. We have shown that HIF1A was a necessary
component for the cytoprotective activity of Q134R and that its activity is based on the stabilization of
HIF1A protein.
6. Patents
Compounds described in the current study are protected by patent #WO2011148208 and
WO2016162706 A1.
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